+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Aerosol Delivery Devices Market by Device Type, Distribution Channel, Therapeutic Class, End User - Global Forecast to 2030- Product Image
Aerosol Delivery Devices Market by Device Type, Distribution Channel, Therapeutic Class, End User - Global Forecast to 2030- Product Image
Sale

Aerosol Delivery Devices Market by Device Type, Distribution Channel, Therapeutic Class, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015031
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Aerosol Delivery Devices Market grew from USD 34.08 billion in 2024 to USD 35.63 billion in 2025. It is expected to continue growing at a CAGR of 4.39%, reaching USD 44.12 billion by 2030.

Revolutionizing Respiratory Care with Aerosol Delivery Innovation

Aerosol delivery devices have become indispensable in the management of respiratory diseases, offering targeted administration of therapeutic agents to the lungs. Over the past decade, advancements in device engineering, patient adherence technologies, and formulation science have converged to transform treatment paradigms. Healthcare providers and patients alike demand solutions that combine precision dosing, ease of use, and minimal side effects. As the global burden of conditions such as asthma, chronic obstructive pulmonary disease, and pulmonary arterial hypertension continues to rise, the stakes for innovation in inhalation therapy have never been higher.

This executive summary synthesizes key findings on market dynamics, regulatory influences, and competitive strategies shaping the aerosol delivery ecosystem. It explores the transformative shifts in segment structures, examines the ramifications of tariff policies in 2025, and distills insights from device typologies, distribution channels, therapeutic classes, and end-user behaviors. Regional nuances and leading corporate initiatives are also highlighted, culminating in actionable recommendations and a transparent overview of our research methodology. Together, these insights form a strategic blueprint for stakeholders aiming to navigate opportunities and challenges in this rapidly evolving landscape

Transformative Shifts Define a Multifaceted Aerosol Delivery Market

In recent years, the aerosol delivery landscape has undergone fundamental transformations driven by technological breakthroughs and shifting consumer expectations. Diversity in device types now spans dry powder inhalers engineered for breath-activated dosing, metered dose inhalers leveraging propellant systems for consistent aerosolization, nebulizers optimized for pulmonary therapy in home and clinical settings, and soft mist inhalers designed to generate fine aerosols with minimal propellant use. Within nebulization, further refinement has given rise to jet nebulizers prized for robustness, mesh nebulizers celebrated for portability, and ultrasonic nebulizers valued for rapid drug dispersion.

Meanwhile, distribution has extended far beyond traditional hospital pharmacies to embrace clinic dispensaries, online pharmacies offering home delivery, and retail pharmacy outlets situated within communities. Therapeutic classes have expanded from allergy management to advanced asthma care encompassing combination therapies, inhaled corticosteroids, long-acting and short-acting beta agonists, and chronic obstructive pulmonary disease interventions that integrate combination therapies, inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. Complementing these trends, end users span the continuum of homecare patients seeking autonomy, hospitalized individuals under critical care, and outpatient clinic attendees requiring routine maintenance therapies. Collectively, these shifts underscore a market defined by segmentation complexity and intensifying competitive pressures

Tariff Pressures Propel Supply Chain Realignments in 2025

The introduction of cumulative United States tariffs in 2025 has injected a new layer of complexity into the aerosol delivery supply chain. Import duties applied to key components-ranging from propellant gases and specialized polymers to precision metering valves-have driven raw material costs upward. Manufacturers have confronted tightened margins, compelling a strategic reassessment of procurement policies and supplier partnerships. In response, several firms have accelerated investments in domestic manufacturing capabilities and alternative material sources to hedge against future tariff adjustments.

Consequently, cost pass-through to healthcare providers and payers has emerged as a critical consideration. Reimbursement negotiations now incorporate tariff-induced pricing pressures, influencing formulary placements and adoption rates. At the same time, these dynamics have opened the door for suppliers who can demonstrate local production footprints or secure long-term supplier agreements exempt from additional duties. As stakeholders adapt to this evolving tariff environment, we anticipate a realignment of global supply chains and an increased emphasis on vertical integration and strategic alliances

Key Segmentation Dynamics Illustrate High-Value Opportunities

Dissecting granular segmentation reveals nuanced growth trajectories and investment priorities. Device type analysis highlights the resurgence of soft mist inhalers due to their enhanced pulmonary deposition and patient adherence advantages, while mesh nebulizers gain traction in homecare settings owing to their portability and quiet operation. Distribution channel insight underscores the accelerated shift toward online pharmacy models as digital platforms streamline direct-to-patient delivery and data-driven adherence support.

Therapeutic class perspectives point to asthma and chronic obstructive pulmonary disease as dual pillars of market demand, with combination therapies and inhaled corticosteroids emerging as the fastest-growing subsegments. The nuanced needs of cystic fibrosis and pulmonary arterial hypertension patients further spur demand for tailored aerosol formulations. In the end-user domain, homecare adoption is expanding as remote care models and telehealth integration empower patients to self-administer therapies under virtual supervision. Collectively, these insights illuminate where R&D investments and commercial efforts will yield the highest returns

Regional Landscapes Reveal Tailored Growth Strategies

Regional analysis underscores stark contrasts in regulatory environments, healthcare infrastructure, and patient demographics. In the Americas, supportive reimbursement policies and established distribution networks continue to drive robust demand for innovative devices, while North American reimbursement reforms encourage cost-effective solutions. Transitioning to Europe, Middle East & Africa, a landscape of heterogeneous regulatory frameworks presents both challenges and openings; Western Europe’s stringent device approval pathways coexist with emerging markets in the Gulf region embracing public-private partnerships to expand respiratory care access.

Meanwhile, the Asia-Pacific region emerges as a focal point for expansion as rising disposable incomes, increasing incidence of air pollution-linked respiratory diseases, and government-led healthcare initiatives converge. China and India, in particular, demonstrate high growth potential driven by localized manufacturing efforts and domestic firms seeking to capture market share. Japan’s emphasis on advanced device automation further enriches the innovation landscape. These regional distinctions inform where market players should prioritize resources and align commercial strategies

Strategic Corporate Moves Shape Future Market Leaders

Leading companies are engaging in strategic initiatives to consolidate their positions and pioneer next-generation aerosol therapies. Global pharmaceutical giants are leveraging strong pipelines in combination therapies, with some firms forming alliances with device manufacturers to co-develop integrated inhalation systems. Pure-play device specialists, meanwhile, focus on digital health integration, embedding sensors and connectivity features that offer adherence tracking and remote monitoring functionalities.

Mergers and acquisitions remain central to portfolio expansion, as evidenced by partnerships that bring together advanced formulation expertise and state-of-the-art device platforms. Companies with established footprints are also seeking to differentiate through patient-centric service offerings, such as device training programs and reimbursement support services. These strategic maneuvers highlight the dual importance of technological innovation and holistic customer engagement in sustaining competitive advantage

Actionable Strategies to Secure Competitive Advantage

Industry leaders should adopt a multi-pronged approach to capitalize on evolving market dynamics. First, diversifying device portfolios across dry powder, soft mist, and nebulizer platforms will meet the varied needs of patient populations and payers. Second, forging partnerships with digital health companies to integrate connectivity features will enhance adherence monitoring and provide actionable patient insights. Third, investing in agile manufacturing capabilities-either through localized production or flexible contract manufacturing-will mitigate tariff risks and accelerate time to market.

Furthermore, engaging early with regulatory authorities and payers to establish value-based reimbursement frameworks will streamline product adoption. Strengthening supply-chain resilience through strategic inventory management and dual-sourcing agreements will safeguard against disruptions. Finally, embedding robust data analytics capabilities within commercial functions will inform dynamic pricing strategies and allow for rapid course corrections in response to competitive threats

Robust Mixed-Method Approach Underlies Comprehensive Insights

Our research methodology synthesizes qualitative and quantitative approaches to ensure accuracy and depth. Primary research involved structured interviews with clinicians, hospital procurement officers, payers, and patient advocacy groups to capture frontline perspectives on device usability, formulary considerations, and adherence challenges. Secondary research drew upon regulatory filings, peer-reviewed journals, industry conference proceedings, and proprietary trade publications to contextualize market trends and technological innovations.

Data triangulation techniques were employed to validate insights, cross-referencing supply-chain metrics with sales data and reimbursement rates. Statistical analysis of segment performance was conducted to identify growth outliers and underpenetrated niches. All findings underwent rigorous expert review to reconcile discrepancies and refine strategic implications. This transparent, multi-layered approach underpins the robustness of the conclusions and recommendations presented

Concluding Perspectives on a Transforming Aerosol Delivery Landscape

In summary, the aerosol delivery domain stands at a pivotal juncture where technological innovation, policy shifts, and evolving patient needs converge. Transformative changes in device typologies and distribution models are reshaping competitive dynamics, while new tariff regimes necessitate agile supply-chain strategies. Granular segmentation analysis exposes high-growth subsegments, and regional nuances underscore the importance of localized approaches. Corporations that align R&D priorities with patient-centric solutions and integrate digital health capabilities will emerge as market leaders. Moreover, dynamic partnerships with regulatory and payer stakeholders will facilitate favorable access pathways.

As the industry transitions toward more personalized, connected inhalation therapies, stakeholders must remain vigilant to external pressures and ready to adapt. The insights and recommendations detailed herein offer a strategic roadmap for navigating this complex landscape, equipping decision-makers with the intelligence needed to seize emerging opportunities and safeguard long-term growth

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Device Type
    • Dry Powder Inhaler
    • Metered Dose Inhaler
    • Nebulizer
      • Jet Nebulizer
      • Mesh Nebulizer
      • Ultrasonic Nebulizer
    • Soft Mist Inhaler
  • Distribution Channel
    • Clinic
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Therapeutic Class
    • Allergy
    • Asthma
      • Combination Therapy
      • Inhaled Corticosteroids
      • Long-Acting Beta Agonists
      • Short-Acting Beta Agonists
    • Chronic Obstructive Pulmonary Disease
      • Combination Therapy
      • Inhaled Corticosteroids
      • Long-Acting Beta Agonists
      • Long-Acting Muscarinic Antagonists
    • Cystic Fibrosis
    • Pulmonary Arterial Hypertension
  • End User
    • Homecare
    • Hospital
    • Outpatient Clinic
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AptarGroup, Inc.
  • West Pharmaceutical Services, Inc.
  • Gerresheimer AG
  • Nemera SAS
  • Berry Global, Inc.
  • Schott AG
  • Rondo-Pak, Inc.
  • Ompi (Recipharm S.A.)
  • Bespak Limited
  • CPI Group Plc

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Aerosol Delivery Devices Market, by Device Type
8.1. Introduction
8.2. Dry Powder Inhaler
8.3. Metered Dose Inhaler
8.4. Nebulizer
8.4.1. Jet Nebulizer
8.4.2. Mesh Nebulizer
8.4.3. Ultrasonic Nebulizer
8.5. Soft Mist Inhaler
9. Aerosol Delivery Devices Market, by Distribution Channel
9.1. Introduction
9.2. Clinic
9.3. Hospital Pharmacy
9.4. Online Pharmacy
9.5. Retail Pharmacy
10. Aerosol Delivery Devices Market, by Therapeutic Class
10.1. Introduction
10.2. Allergy
10.3. Asthma
10.3.1. Combination Therapy
10.3.2. Inhaled Corticosteroids
10.3.3. Long-Acting Beta Agonists
10.3.4. Short-Acting Beta Agonists
10.4. Chronic Obstructive Pulmonary Disease
10.4.1. Combination Therapy
10.4.2. Inhaled Corticosteroids
10.4.3. Long-Acting Beta Agonists
10.4.4. Long-Acting Muscarinic Antagonists
10.5. Cystic Fibrosis
10.6. Pulmonary Arterial Hypertension
11. Aerosol Delivery Devices Market, by End User
11.1. Introduction
11.2. Homecare
11.3. Hospital
11.4. Outpatient Clinic
12. Americas Aerosol Delivery Devices Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Aerosol Delivery Devices Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Aerosol Delivery Devices Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AptarGroup, Inc.
15.3.2. West Pharmaceutical Services, Inc.
15.3.3. Gerresheimer AG
15.3.4. Nemera SAS
15.3.5. Berry Global, Inc.
15.3.6. Schott AG
15.3.7. Rondo-Pak, Inc.
15.3.8. Ompi (Recipharm S.A.)
15.3.9. Bespak Limited
15.3.10. CPI Group Plc
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. AEROSOL DELIVERY DEVICES MARKET MULTI-CURRENCY
FIGURE 2. AEROSOL DELIVERY DEVICES MARKET MULTI-LANGUAGE
FIGURE 3. AEROSOL DELIVERY DEVICES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AEROSOL DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. AEROSOL DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. AEROSOL DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY JET NEBULIZER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY MESH NEBULIZER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY SOFT MIST INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY LONG-ACTING MUSCARINIC ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL AEROSOL DELIVERY DEVICES MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. CANADA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 57. CANADA AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 58. CANADA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. CANADA AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 60. CANADA AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 61. CANADA AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 62. CANADA AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. MEXICO AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 64. MEXICO AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 65. MEXICO AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. MEXICO AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 68. MEXICO AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. GERMANY AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 100. GERMANY AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 101. GERMANY AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. GERMANY AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 103. GERMANY AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 104. GERMANY AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 105. GERMANY AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. FRANCE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 107. FRANCE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 108. FRANCE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. FRANCE AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 110. FRANCE AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 111. FRANCE AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 112. FRANCE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. ITALY AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 121. ITALY AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 122. ITALY AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. ITALY AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 124. ITALY AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 125. ITALY AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 126. ITALY AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. SPAIN AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 128. SPAIN AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 129. SPAIN AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. SPAIN AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 131. SPAIN AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 132. SPAIN AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 133. SPAIN AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 142. SAUDI ARABIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 143. SAUDI ARABIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. SAUDI ARABIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 145. SAUDI ARABIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 146. SAUDI ARABIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 147. SAUDI ARABIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 149. SOUTH AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 150. SOUTH AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. SOUTH AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 152. SOUTH AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 153. SOUTH AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 154. SOUTH AFRICA AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. DENMARK AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 156. DENMARK AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 157. DENMARK AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. DENMARK AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 159. DENMARK AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 160. DENMARK AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 161. DENMARK AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. QATAR AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 170. QATAR AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 171. QATAR AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. QATAR AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 173. QATAR AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 174. QATAR AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 175. QATAR AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. FINLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 177. FINLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 178. FINLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. FINLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 180. FINLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 181. FINLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 182. FINLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 184. SWEDEN AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 185. SWEDEN AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. SWEDEN AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 187. SWEDEN AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 188. SWEDEN AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 189. SWEDEN AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 191. NIGERIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 192. NIGERIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. NIGERIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 194. NIGERIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 195. NIGERIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 196. NIGERIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. EGYPT AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 198. EGYPT AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 199. EGYPT AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. EGYPT AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 201. EGYPT AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 202. EGYPT AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 203. EGYPT AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. TURKEY AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 205. TURKEY AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 206. TURKEY AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. TURKEY AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 208. TURKEY AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 209. TURKEY AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 210. TURKEY AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 217. ISRAEL AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. NORWAY AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 219. NORWAY AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 220. NORWAY AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. NORWAY AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 222. NORWAY AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 223. NORWAY AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 224. NORWAY AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. POLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 226. POLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 227. POLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. POLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 229. POLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 230. POLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 231. POLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 233. SWITZERLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 234. SWITZERLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. SWITZERLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 236. SWITZERLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 237. SWITZERLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 238. SWITZERLAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 247. CHINA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 248. CHINA AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 249. CHINA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. CHINA AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 251. CHINA AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 252. CHINA AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 253. CHINA AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. INDIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 255. INDIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 256. INDIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. INDIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 258. INDIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 259. INDIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 260. INDIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. JAPAN AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 262. JAPAN AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 263. JAPAN AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. JAPAN AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 265. JAPAN AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 266. JAPAN AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 267. JAPAN AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 279. SOUTH KOREA AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 280. SOUTH KOREA AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 281. SOUTH KOREA AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 284. INDONESIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. INDONESIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 286. INDONESIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 287. INDONESIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 288. INDONESIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. THAILAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 290. THAILAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 291. THAILAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. THAILAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 293. THAILAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 294. THAILAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 295. THAILAND AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 300. PHILIPPINES AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 301. PHILIPPINES AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 302. PHILIPPINES AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 305. MALAYSIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. MALAYSIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 307. MALAYSIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 308. MALAYSIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 309. MALAYSIA AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZER, 2018-2030 (USD MILLION)
TABLE 312. SINGAPORE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 313. SINGAPORE AEROSOL DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 314. SINGAPORE AEROSOL DELIVERY DEVICES MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 315. SINGAPORE AEROSOL DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018-2030 (USD MILLION)
TABLE 316. SINGAPORE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. VIETNAM AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 318. VIETNAM AEROSOL DELIVERY DEVICES MARKET SIZE, BY

Companies Mentioned

The companies profiled in this Aerosol Delivery Devices market report include:
  • AptarGroup, Inc.
  • West Pharmaceutical Services, Inc.
  • Gerresheimer AG
  • Nemera SAS
  • Berry Global, Inc.
  • Schott AG
  • Rondo-Pak, Inc.
  • Ompi (Recipharm S.A.)
  • Bespak Limited
  • CPI Group Plc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 35.63 Billion
Forecasted Market Value ( USD ) by 2030 $ 44.12 Billion
Compound Annual Growth Rate4.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Aerosol Delivery Devices Market Report by Product, Application, Distribution Channel, and Region 2025-2033 - Product Image

Aerosol Delivery Devices Market Report by Product, Application, Distribution Channel, and Region 2025-2033

  • Report
  • 135 Pages
  • Global
From
Aerosol Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Aerosol Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Aerosol Delivery Devices Market Report 2025 - Product Image

Aerosol Delivery Devices Market Report 2025

  • Report
  • 200 Pages
  • Global
From
2025 Global Forecast for Aerosol Delivery Device Market (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Aerosol Delivery Device Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
The Mechanics of Inhaled Pharmaceutical Aerosols. An Introduction. Edition No. 2 - Product Image

The Mechanics of Inhaled Pharmaceutical Aerosols. An Introduction. Edition No. 2

  • Book

About the Market

The Aerosol Delivery Device market is composed of two main categories: Inhalers and Nebulisers. Inhalers are devices that deliver medication directly to the lungs in the form of a mist or spray. They are typically used to treat asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Nebulisers are devices that convert liquid medication into a fine mist that can be inhaled. They are typically used to treat more severe respiratory conditions, such as cystic fibrosis. Inhalers and nebulisers are both used to deliver medication to the lungs, but they differ in terms of their size, portability, and ease of use. Inhalers are typically smaller and more portable than nebulisers, making them more convenient for patients to carry and use. Inhalers also require less coordination and effort to use than nebulisers, making them easier for patients to use. Some companies in the Aerosol Delivery Device market include GlaxoSmithKline, Boehringer Ingelheim, Novartis, and Teva Pharmaceuticals. Other companies include 3M, Philips, and Omron Healthcare. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.